Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05145686
Other study ID # Ege U.Eth. Com.16-7/14
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 1, 2018
Est. completion date December 1, 2019

Study information

Verified date December 2021
Source Ege University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Matrix metalloproteinases (MMPs) are important zinc enzyme group that responsible for reducing extracellular matrix components. It has been reported that MMPs play an important role in pulpal inflammation. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Matris metalloproteinase -2, -8, -9 expressions
. The aims of this in vivo study was to compare the expression levels of MMP-2, -8 and -9 in primary molars with reversible and irreversible pulpitis and to compare the clinically and radiographically success of MTA and Biodentine materials at the end of 18 months.

Locations

Country Name City State
Turkey Ege University Izmir

Sponsors (1)

Lead Sponsor Collaborator
Ege University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary The role of MMP-2, 8 and 9 in reversible and irreversible pulpitis The expression levels of MMP-2, 8 and 9 were detected 18 months
Primary Comparison of the clinical and radiographic success of MTA and Biodentine in primary teeth pulpotomy treatment MTA and Biodentine materials were used in primary molars with reversible pulpitis. At the end of 6, 12 and 18 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption. 18 months
See also
  Status Clinical Trial Phase
Completed NCT05167123 - Pulp Capping in Primary Molars Using TheraCal (LC) Phase 4
Recruiting NCT05144711 - Management of Deep Carious Lesions in Adults N/A
Completed NCT01224925 - RCT of Pulp Capping Over Carious Exposure in Adults N/A
Completed NCT03284697 - Direct Pulp Capping With MTA and Calcium Hydroxide. N/A
Completed NCT03286959 - Effect of Liners on Pulpal Outcome and Restoration Survival After Partial Caries Excavation N/A
Completed NCT04167943 - Conservative Pulp Therapy of Primary Molars Using TheraCAL Phase 3
Enrolling by invitation NCT02702505 - Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT Phase 4
Active, not recruiting NCT05878249 - Role Of Wound Lavage in Direct Pulp Capping Of Permanent Teeth With Carious Exposure N/A
Not yet recruiting NCT06433297 - Comparative Evaluation of Indirect vs. Direct Pulp Capping in Deep Carious Mandibular Molars N/A
Not yet recruiting NCT04617600 - Survival Rate After TheraCal PT Pulpotomy Versus MTA Pulpotomy in Children With Vital Primary Molars. N/A
Terminated NCT01622153 - Electrical and Formocresol Pulpotomy in Primary Molars N/A
Active, not recruiting NCT03186690 - Similar Outcomes of Vital Pulp Therapy Using Mineral Trioxide Aggregate or Biodentine™ N/A
Active, not recruiting NCT03071588 - Assessment of a New Protocol for Indirect Pulp Capping Procedures N/A
Active, not recruiting NCT02201641 - Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial Phase 4
Recruiting NCT03741816 - Indirect Pulp Capping With Biodentine and TheraCal LC in Permanent Mature Molars N/A
Completed NCT04365270 - Antibacterial Effect and Clinical Performance of Chitosan Modified Glass Ionomer Phase 3
Completed NCT00187837 - The CAP-1 Trial: Stepwise Excavation Versus One Completed Excavation in Deep Caries N/A
Active, not recruiting NCT04374214 - Effect of Simvastatin as Pulpotomy Agent in Cariously Exposed Permanent Molars N/A
Recruiting NCT06435065 - Direct Pulp Capping Agent on Human Pulp Tissue Phase 4
Not yet recruiting NCT04807244 - Treatment of Deep Carious Lesions With Selective Caries Removal, Partial or Full Pulpotomy N/A